1. Kato, E, Sawada, T, Tahara, K, et al. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis 2017; 20: 839–845.
Google Scholar | Crossref | Medline2. Treharne, GJ, Douglas, KM, Iwaszko, J, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care 2007; 5: 175–190.
Google Scholar | Crossref | Medline3. Jones, G, Sebba, A, Gu, J, et all. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88–96.
Google Scholar | Crossref | Medline | ISI4. Gabay, C, Emery, P, van Vollenhoven, R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381: 1541–1550.
Google Scholar | Crossref | Medline | ISI5. Koike, T, Harigai, M, Inokuma, S, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 2014; 41: 15–23.
Google Scholar | Crossref | Medline6. Mueller, RB, Kaegi, T, Finckh, A, SCQM physicians, et al. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford) 2014; 53: 671–677.
Google Scholar | Crossref | Medline | ISI7. Arnett, FC, Edworthy, SM, Bloch, DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324.
Google Scholar | Crossref | Medline8. Aletaha, D, Neogi, T, Silman, AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–2581.
Google Scholar | Crossref | Medline9. Prevoo, MLL, Van’T Hof, MA, Kuper, HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of a patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–48.
Google Scholar | Crossref | Medline10. Aletaha, D, Nell, VPK, Stamm, T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796–R806.
Google Scholar | Crossref | Medline11. Aletaha, D, Landewe, R, Karonitsch, T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008; 59: 1371–1377.
Google Scholar | Crossref | Medline12. Bruce, B, Fries, JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005; 23(Suppl 39): S14–S18.
Google Scholar | Medline13. Genevay, S, Finckh, A, Ciurea, A, et al. Physicians of the Swiss clinical quality management program for rheumatoid arthritis. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 57: 679–685.
Google Scholar | Crossref | Medline14. Pers, YM, Schaub, R, Constant, E, et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine 2015; 82(1): 25–30.
Google Scholar | Crossref | Medline15. Kawashiri, SY, Kawakami, A, Iwamoto, N, et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol 2011; 21: 365–369.
Google Scholar | Crossref | Medline16. Smolen, JS, Aletaha, D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011; 63: 43–52.
Google Scholar | Crossref | Medline17. Mori, S, Yoshitama, T, Hidaka, T, et al. Conparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan. PLOS one 2017; 12(6): e0179179. DOI: 10.1371/journal.pone.0179179.eCollection2017.
Google Scholar | Crossref | Medline18. Nishimoto, N, Miyasaka, N, Yamamoto, K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12–19.
Google Scholar | Medline | ISI19. Nishimoto, N, Hashimoto, J, Miyasaka, N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162–1167.
Google Scholar | Crossref | Medline | ISI20. Mori, S, Yoshitama, T, Abe, Y, et al. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study. Rheumatology 2019; 58: 1274–1284.
Google Scholar | Crossref | Medline21. Saraux, A, Rouanet, S, Flipo, RM, et al. Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study. Clin Exp Rheumatol 2016; 34: 303–310.
Google Scholar | Medline22. Pease, CT, Bhakta, BB, Devlin, J, et al. Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors. Rheumatology (Oxford) 1999; 38: 228–234.
Google Scholar | Crossref | Medline | ISI